Metabolic Health in Motion

Friday, September 19, 2025, 8:00 AM - Saturday, September 20, 2025, 5:00 PM, Hyatt Regency Coralville, Coralville, IA

Metabolic associated steatotic liver disease (MASLD) has become the most common chronic liver disease worldwide, affecting nearly a quarter of the global population. The rising incidence of obesity, diabetes, and metabolic syndrome has driven this surge, making MASLD a leading cause of advanced liver disease, including cirrhosis and hepatocellular carcinoma. As these conditions progress, MASLD is expected to surpass alcohol and viral hepatitis as the leading indication for liver transplantation globally, contributing significantly to healthcare burdens. Liver transplant remains the only effective curative treatment for decompensated-cirrhosis, and it is a limited resource. That, in combination with the particular challenges that MASLD patients’ management pose, make it indispensable to focus on increased awareness to promote early diagnosis of MASLD and preventive strategies. Aimed at the medical community, a series of lectures to review the state of the art of this important issue will be scheduled. Different levels of care and several medical specialties will be involved to provide a holistic overview.Over the course of two days, international expert speakers will review the state of the art in MASLD. This update will include epidemiology, risk factors, etiology, disease progression, lifestyle changes (dietary modifications, exercise programs), pharmacological treatments, endoscopic treatments, surgical treatments, liver transplantation, donation and outcomes.

AMA PRA Category 1 Credits™ (13.50 hours), AAPA Category 1 CME credit (13.50 hours), ANCC Contact Hours (13.50 hours), Non-Physician Attendance (13.50 hours)

1. Raise awareness on MASLD and its consequences on health, including end-stage liver disease.
2. Review the state of the art on MASLD and update the medical community on health goals for these patients.
3. Enhance professional knowledge and skills through interactive sessions and networking opportunities with experts.
4. Comprehensive Understanding of MASLD: Describe the origins, diagnosis, natural history, and pathophysiology of MASLD, distinguishing it from other liver diseases.
5. Epidemiology and Prevention: Analyze the epidemiology of MASLD and evaluate effective prevention strategies from a public health perspective.
6. Risk Assessment and Management: Develop evidence-based approaches for assessing and managing cardiovascular risk, cancer risk, and alcohol-related liver disease in patients with MASLD.
7. Lifestyle and Therapeutic Interventions: Implement personalized lifestyle interventions, including dietary modifications and exercise programs, and assess the latest pharmacological, endoscopic, and surgical treatment options for MASLD.
8. Multidisciplinary Collaboration: Design and sustain a multidisciplinary MASLD clinic, fostering collaboration across specialties to optimize patient outcomes.
9. Transplantation Considerations: Identify and address the challenges of liver transplantation in MASH cirrhotic patients, including perioperative, anesthetic, and surgical considerations, as well as post-transplant care.

Regular Registration: through September 12, 2025

• Physicians - $130.00

• Pharmacists & Other Health Professionals - $65.00

• Trainees - Students, Residents & Fellows - $50.00

Virtual Only Registration:

• Physicians - $100.00

• Pharmacists & Other Health Professionals - $65.00

• Trainees - Students, Residents & Fellows - $40.00

Late Registration: from September 12, 2025 - day of conference

• Physicians - $150.00

• Pharmacists & Other Health Professionals - $80.00

• Trainees - Students, Residents & Fellows - $65.00

Cancellation Policy: If cancellation is requested prior to September 12, 2025, a full refund is available. If cancellation is requested September 12, 2025 or later, a refund minus a $50.00 cancellation fee is available. If necessary, send cancellation request to [email protected].

In support of improving patient care, the University of Iowa Roy J. and Lucille A. Carver College of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurse: The University of Iowa Roy J. and Lucille A. Carver College of Medicine designates this activity for a maximum of 13.50 ANCC contact hours.

Physician: The University of Iowa Roy J. and Lucille A. Carver College of Medicine designates this live activity for a maximum of 13.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Physician Associate: The University of Iowa Roy J. and Lucille A. Carver College of Medicine has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 13.50 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Other Health Care Provider: A certificate of participation will be available after successful completion of an online evaluation. It is the responsibility of the licensees to determine if this continuing education activity meets the requirements of their professional licensure board.

Mitigation of Relevant Financial Relationships

University of Iowa Roy J. and Lucille A. Carver College of Medicine adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships have been mitigated prior to the commencement of the activity.